Media Release: Molecular Imaging in NSW
The Cyclotek group are pleased to announce the completion of their purchase of the PETTECH Solutions FDG business. The new entity, Cyclotek NSW Pty Ltd is a wholly owned subsidiary of Cyclotek (Aust) Pty Ltd.
PETTECH Solutions is an Australian leader in the radiopharmaceuticals market. We partner with our customers to deliver reliable and innovative health solutions. We drive the industry forward with education and a collaborative approach that provides better patient outcomes. We maintain high standards to ensure that safety, innovation and customer satisfaction are the number one priority.
Latest Educational Events
PART 3: Multidisciplinary Management of Brain Metastases in the Age Immunotherapy
PART 2: Multidisciplinary Management of Brain Metastases in the Age Immunotherapy
PART 1: Multidisciplinary Management of Brain Metastases in the Age Immunotherapy
The PETTECH facility is state-of-the-art PET radiopharmaceutical production facility built in Sydney’s south, consists of two Siemens cyclotrons which produce the short-lived radiopharmaceutical 18F FDG (fluorodeoxyglucose) used in PET/CT scanning and supplied to PET/CT facilities. 18F synthesised isotopes have a half life of 110 minutes which is enough time to manufacture, deliver and scan patients so that diagnosis and treatment programs can be completed and implemented for better patient outcomes.
In Australia PET/CT is predominantly used in the diagnosis of numerous cancers and is becoming integral in the working up of patient cases in hospital MDT (multi-disciplinary teams) which has become the preferred format for case discussions within the Hospital environment.
In Australia, manufacture of all radiopharmaceuticals is regulated by the Therapeutic Goods Administration (TGA). PETTECH Solutions currently holds a licence to manufacture Therapeutic Goods issued by the TGA and manufactures under Good Manufacturing Practice (GMP) conditions.
Patients can be assured of the quality of PETTECH products as PETTECH is the only commercial supplier in Australia to have obtained an Aust R registration for 18F FDG (fludeoxyglucose). Patients can be confident that product quality and purity is maintained right from production to labelled expiration time as the products comply with all relevant Commonwealth and State regulations.
State of the art
medical know how.